LAW OFFICES OF



Synnestvedt & Lechner Llp

2600 ARAMARK TOWER

IIOI MARKET STREET

PHILADELPHIA, PA 19107-2950

TELEPHONE (215) 923-4466

FACSIMILE (215) 923-2189 E-MAIL synnlech@synnlech.com www.synnlech.com

October 17, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re/ Application of C. Icard-Liepkalns, J. Mallet,

and P. Ravassard Application No. 09/595,947 Filed June 16, 2000 Examiner: C-M. Kam Art Unit: 1653

Confirmation No.: 2918

Polypeptides of the "Basic-Loop-Helix" bHLH Family, Corresponding Nucleic Acid Sequences

Attorney Docket No. P26,952 USA

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope, postage prepaid, addressed to Mail Stop Sequence, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on October 17, 2003.

Lynn M. White

Mail Stop Sequence Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Statement under 37 C.F.R. §§1.821(f), 1.821(g), and 1.825(a) Regarding Subsequent Sequence Listing Submissions

Sir:

STATEMENT

In accordance with 37 C.F.R. §§1.821(f), 1.821(g), and 1.825(a) relating to submissions containing Sequence Listings after the time of filing of the application, the undersigned hereby certifies that:

- (A) the Sequence Listing information recorded in computer readable form is identical to the written Sequence Listing, pursuant to 37 C.F.R. §1.821(f); and
- (B) the present submission contains no new matter, pursuant to 37 C.F.R. §1.821(g).

Respectfully submitted,

Patrick J. Kelly, Ph.D. Registration No. 34,638

SYNNESTVEDT & LECHNER LLP Suite 2600 Aramark Tower 1101 Market Street Philadelphia, PA 19107 (215) 923-4466

M:\JDermott\Gencell\26,952 USA\sequence cert.wpd

No.: 09/595,947

CONTAINING NOT HE TO COMPLY WITH REQUIREMENTS FOR PATENT APPL NUC . EOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Appli : nt must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The Liceotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

x	1.	This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2.	This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.F. 1.821(c).
	3.	A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4.	A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5.	The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6.	The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
x	7.	Other: Figs. 1, 2 and 4 have nucleotide and amino acid sequences, however, the sequence listing does not include these sequences.
	Ap	pplicant Must Provide:
	An	initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
X		initial of deboticate deliptics reducible form (Ord) copy of the dequence Listing.
x	An	initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into especification.
	An the	initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into especification. Statement that the content of the paper and computer readable copies are the same and, where applicable, lude no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g).
x	An the	initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into especification.

PE CONTROL TO THE PROPERTY OF THE PROPERTY OF

LAW OFFICES OF

Synnestvedt & Lechner llp

2600 ARAMARK TOWER
HOL MARKET STREET
PHILADELPHIA, PA 19107-2950
TELEPHONE (215) 923-4466

FACSIMILE (215) 923-2189 E-MAIL synnlech@synnlech.com www.synnlech.com

October 17, 2003

Boxseg/1653 \$

OCT 2 7 2003
TECH LENTER 1600/2900

Examiner: C-M. Kam

Confirmation No.: 2918

Art Unit: 1653

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re/ Application of C. Icard-Liepkalns, J. Mallet, and P. Ravassard Application No. 09/595,947 Filed June 16, 2000

Polypeptides of the "Basic-Loop-Helix" bHLH Family, Corresponding Nucleic Acid Sequences

Attorney Docket No. P26,952 USA

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope, postage prepaid, addressed to Mail Stop Sequence, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on October 17, 2003.

Lynn M. White

Mail Stop Sequence Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

> Reply to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated April 17, 2003

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated April 17, 2003 (hereafter "the Notice"), enclosed herewith are the following:

- (A) A preliminary amendment incorporating a properly formatted Sequence
 Listing into the specification of the above-identified application;
- (B) one diskette containing the Sequence Listing in computer-readable form;
- the required statement concerning submissions of Sequence Listings subsequent to filing of the application, pursuant to 37 C.F.R. §§1.821(f), 1.821(g), and 1.825(a);
- (D) a copy of the Notice;
- (E) a petition for a five-month extension of time under 37 C.F.R. §§1.136(a); and
- (F) a check for \$2,010.00 in payment of the extension fee.

The Commissioner is hereby authorized to charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 19-5425. A duplicate of this paper is enclosed for charging purposes.

Respectfully submitted,

Patrick J. Kelly, Ph.D. Registration No. 34,638

SYNNESTVEDT & LECHNER LLP Suite 2600 Aramark Tower 1101 Market Street Philadelphia, PA 19107 (215) 923-4466

M:\JDermott\Gencell\26,952 USA\sequence listing tml.wpd